BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced on 5/24/18 that BioMarin received standard approval from the U.S. Food and Drug Administration (FDA) for Palynziq (pegvaliase-pqpz) Injection to reduce blood phenylalanine (Phe) concentrations in adult patients with phenylketonuria (PKU), who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management.